Emmett-Phil Coriat


Supporting businesses to build an alliance with nature for change towards regenerative performance and value creation.

Want to know more?

Emmett-Phil brings a 25-year track record of driving Biotech/Medtech transactions and shareholder value: fundraising, non-dilutive financing (e.g. pharma partnerships) and M&A. He was based in Boston from 2016 to 2018 and now shares his time between Europe and North America.

Emmett-Phil joined AEC Partners in 2008 to lead the creation of a Healthcare Innovation practice focused on Biotech/Medtech startups. Its success rests on a mix of strong strategic, fundraising and business development expertise. Driven by major transactions and strategic support to Biotechs, MedTech and e-health start-ups, it has become a significant pillar of AEC Partners’ business.

Emmett-Phil was previously a partner at T2C2 Capital, a VC fund behind companies such as Enobia Pharma (acquired by Alexion Pharmaceuticals for $1,080M in 2011). He was co-founder & CEO of Mimetogen Pharmaceuticals, a McGill University spin-off acquired by Allergan in 2015.

In 2021, he founded Natural Leadership Institute (natureandleadership.com) to boost psychological safety, collective performance and innovation in companies through nature-based programs.

He holds a B. Pharm (Université de Montréal), an MBA (London Business School), a Diploma in Intellectual Property management (McGill University) and is certified in ecotherapy. He is fluent in English, French, Spanish, Hebrew and Italian. He is Canadian and Spanish.